Pioneering clinical-stage mucosal vaccine platform.
↓
The Platform
Our state-of-the-art platform for producing first-in-class mucosal vaccines uses Newcastle Disease Virus (NDV) to enable rapid development of safe and highly immunogenic viral vectors that are easy to deliver.
The Products
The COVID-19 pandemic provided a global stage - and a worthy challenge - to test the APMV/NDV Platform. However, COVID-19 vaccines are just the beginning. Explore our products and our pipeline of extraordinary possibilities.
The Possibilities
The vast majority of vaccines for respiratory diseases are administered via systemic delivery, and therefore do not induce mucosal immunity. Our innovative mucosal vaccine platform will bring us safe and more effective vaccines for all humans, everywhere.
Enabling our world to quickly and effectively prepare for the next pandemic.
Latest News
Featured
